However, HRR-defective cancer cells, including cells with BRCA1/2 mutations, cannot repair this damage and die.7 Thus, although drug resistance may arise, PARP inhibitors can selectively eradicate HRR-deficient cancer cells. Here, BRCA1 is linked to cancer.